<DOC>
	<DOCNO>NCT03064854</DOCNO>
	<brief_summary>The primary purpose study establish maximum tolerate dose ( MTD ) and/or recommend dose expansion ( RDE ) PDR001 administer combination platinum-doublet chemotherapy treatment naive patient PD-L1 unselected , advanced NSCLC , estimate preliminary anti-tumor activity PDR001 combination platinum-doublet chemotherapy patient population .</brief_summary>
	<brief_title>PDR001 Combination With Platinum-doublet Chemotherapy PD-L1 Unselected , Metastatic NSCLC Patients ( ElevatION : NSCLC-101 Trial )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Main 1 . Patient stage IIIB ( candidate definitive multimodality therapy ) stage IV NSCLC relapse locally advanced metastatic NSCLC follow : 1 . Group A , group B group C : Patients previously treat systemic anticancer therapy ( e.g . cytotoxic drug , target therapy , monoclonal antibody therapy include immunotherapy ( e.g . PD1/PDL1 inhibitor ) target therapy , either experimental ) , exception neoadjuvant adjuvant therapy depict inclusion criterion 4 . 2 . Group D : Patients receive one prior systemic therapy treatment consist PD1 and/or PDL1 inhibitor without CTLA4 inhibitor NSCLC , exception neoadjuvant adjuvant therapy depict inclusion criterion 4 . The last dose prior immunotherapy must administer least 6 week prior start study treatment ( cycle 1 day 1 ) . 2 . Histologically cytologically confirm diagnosis NSCLC EGFR Wildtype , ALKnegative rearrangement ROS1negative rearrangement 3 . Eastern Cooperative Oncology Group ( ECOG ) performance status 01 4 . Patients least 1 measurable tumor lesion assess Computed Tomography ( CT ) Scan Magnetic Resonance Imaging ( MRI ) accord RECIST 1.1 . Main 1 . Patient history severe hypersensitivity reaction plan study treatment include gemcitabine , paclitaxel , cisplatin , carboplatin , pemetrexed know excipients drug 2 . History severe hypersensitivity reaction monoclonal antibody , opinion investigator may pose increase risk serious infusion reaction . 3 . Patient history interstitial lung disease interstitial pneumonitis , include clinically significant radiation pneumonitis ( i.e. , affecting activity daily live require therapeutic intervention ) . 4 . History leptomeningeal metastasis 5 . Active , know suspected autoimmune disease document history autoimmune disease , include ulcerative colitis Crohn 's disease ( Patients vitiligo , type I diabetes mellitus , residual hypothyroidism due autoimmune condition require hormone replacement , psoriasis require systemic treatment , condition expect recur absence external trigger permit enroll ) . 6 . Use live vaccine infectious disease within 4 week initiation study treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>PDR001</keyword>
	<keyword>immunotherapy</keyword>
	<keyword>Non-small cell lung cancer</keyword>
	<keyword>lung</keyword>
	<keyword>NSCLC</keyword>
</DOC>